##SAMPLE=<ID=Normal2,IsTumor=no>
##SAMPLE=<ID=Tumor2,IsTumor=yes>
##ANALYSISTYPE=SOMATIC_PAIR
##DESCRIPTION=tumor_af=Mutant allele frequency in tumor (Sample Tumor2).
##DESCRIPTION=tumor_dp=Tumor Depth (Sample Tumor2).
##DESCRIPTION=normal_af=Mutant allele frequency in normal (Sample Normal2).
##DESCRIPTION=normal_dp=Normal depth (Sample Normal2).
##DESCRIPTION=filter=Filter criteria from vcf file.
##DESCRIPTION=snp_q=Quality parameters - SNP quality (QUAL).
##DESCRIPTION=gene=Affected gene list (comma-separated).
##DESCRIPTION=variant_type=Variant type.
##DESCRIPTION=coding_and_splicing=Coding and splicing details (Gene, NM number, type, impact, exon number, HGVS.c, HGVS.p).
##DESCRIPTION=interpro=Interpro domains.
##DESCRIPTION=RepeatMasker=RepeatMasker annotation.
##DESCRIPTION=dbSNP=Identifier in dbSNP database.
##DESCRIPTION=1000g=Allele frequency in all populations of 1000g project.
##DESCRIPTION=ExAC=Allele frequency in all populations of ExAC project.
##DESCRIPTION=gnomAD=Allele frequency in gnomAD database.
##DESCRIPTION=COSMIC=COSMIC somatic variant database anntotation.
##DESCRIPTION=OMIM=OMIM database annotation.
##DESCRIPTION=ClinVar=ClinVar database annotation.
##DESCRIPTION=HGMD=HGMD database annotation.
##DESCRIPTION=phyloP=phyloP (100way vertebrate) annotation. Deleterious threshold > 1.6.
##DESCRIPTION=MetaLR=MetaLR effect prediction: D=damaging, T=tolerated.
##DESCRIPTION=Sift=Sift effect prediction: D=damaging, T=tolerated.
##DESCRIPTION=PolyPhen2=Polyphen2 (HVAR) effect prediction: D=probably damaging, P=possibly damaging, B=benign.
##DESCRIPTION=FATHMM=FATHMM effect prediction: D=damaging, T=tolerated.
##DESCRIPTION=CADD=CADD pathogenicity prediction scores (scaled phred-like). Deleterious threshold > 15-20.
##DESCRIPTION=ihdb_hom=Homozygous variant counts in NGSD for the same processing system.
##DESCRIPTION=ihdb_het=Heterozyous variant counts in NGSD for the same processing system.
##DESCRIPTION=ihdb_wt=Wildtype variant counts in NGSD for the same processing system.
##DESCRIPTION=ihdb_allsys_hom=Homozygous variant counts in NGSD independent of the processing system.
##DESCRIPTION=ihdb_allsys_het=Heterozygous variant counts in NGSD independent of the processing system.
##DESCRIPTION=classification=Classification from the NGSD.
##DESCRIPTION=classification_comment=Classification comment from the NGSD.
##DESCRIPTION=validated=Validation information from the NGSD. Validation results of other samples are listed in brackets!
##DESCRIPTION=comment=Comments from the NGSD. Comments of other samples are listed in brackets!
##DESCRIPTION=gene_info=General gene information from the NGSD.
##DESCRIPTION=som_ihdb_c=Somatic variant count within NGSD.
##DESCRIPTION=som_ihdb_p=Projects with somatic variant in NGSD.
##FILTER=fv.not_cod_spli=Not a coding or splicing variant (filter_vcf).
##FILTER=fv.off_target=Variant is off target (filter_vcf).
##FILTER=fv.somca_all_freq=Allele frequencies in tumor < 0.05 or allele frequencies in normal > 0.01 (filter_vcf).
##FILTER=fv.somca_db_frequencies=Allele frequencies in public databases are > 0.01 (filter_vcf).
##FILTER=fv.somca_depth_norm=Sequencing depth normal is too low < 100 (filter_vcf).
##FILTER=fv.somca_depth_tum=Sequencing depth tumor is too low < 100 (filter_vcf).
##FILTER=off-target=Variant outside the panel/exome target region.
##FILTER=s.special_chromosome=Special chromosome.
##DESCRIPTION=CGI_drug_assoc=Cancer Genome Interpreter - therapeutic biomarkers
##DESCRIPTION=CGI_evid_level=Cancer Genome Interpreter - evidence level
##DESCRIPTION=CGI_transcript=Cancer Genome Interpreter - transcript to use
#chr	start	end	ref	obs	tumor_af	tumor_dp	normal_af	normal_dp	filter	snp_q	gene	variant_type	coding_and_splicing	interpro	Pathway_KEGG_full	Function_description	Pathway_BioCarta_full	RepeatMasker	dbSNP	1000g	ExAC	gnomAD	COSMIC	OMIM	ClinVar	HGMD	phyloP	MetaLR	Sift	PolyPhen2	FATHMM	CADD	ihdb_hom	ihdb_het	ihdb_wt	ihdb_allsys_hom	ihdb_allsys_het	classification	classification_comment	validated	comment	gene_info	som_ihdb_c	som_ihdb_p	CGI_drug_assoc	CGI_evid_level	CGI_transcript
chr1	158494511	158494511	G	T	0.3839	211	0.0000	246	fv.not_cod_spli;fv.off_target;off-target	340	RP11-144L1.8	non_coding_transcript_exon_variant	RP11-144L1.8:ENST00000436135:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.1050G>T:							0.0000	0.0000	0.0000														0	0					RP11-144L1.8 (inh=n/a pLI=n/a)	1	SomaticAndTreatment,			
chr1	206658554	206658554	C	T	0.4481	183	0.0000	332	off-target	486	IKBKE	synonymous_variant	IKBKE:ENST00000367120:synonymous_variant:LOW:exon15/22:c.1527C>T:p.Cys509Cys,IKBKE:ENST00000537984:synonymous_variant:LOW:exon14/21:c.1272C>T:p.Cys424Cys		Toll-like receptor signaling pathway	Phosphorylates inhibitors of NF-kappa-B thus leading to the dissociation of the inhibitor/NF-kappa-B complex and ultimately the degradation of the inhibitor. May play a special role in the immune response. Protects cells against DNA damage- induced cell death				0.0000	0.0000	0.0000														0	0					IKBKE (inh=n/a pLI=0.80)	1	SomaticAndTreatment,			
chr1	228164314	228164314	G	A	0.2917	24	0.0000	59	fv.not_cod_spli;fv.off_target;fv.somca_depth_tum;fv.somca_depth_norm;off-target	93	CICP26	non_coding_transcript_exon_variant	CICP26:ENST00000425003:non_coding_transcript_exon_variant:MODIFIER:exon1/3:n.1581C>T:							0.0000	0.0000	0.0000														0	0					CICP26 (inh=n/a pLI=n/a)	1	SomaticAndTreatment,			
chr1	233355150	233355150	G	A	0.4375	32	0.0000	42	fv.not_cod_spli;fv.off_target;fv.somca_depth_tum;fv.somca_depth_norm;off-target	107	PCNXL2	intron_variant	PCNXL2:ENST00000258229:intron_variant:MODIFIER:exon10/33:c.2505-1220C>T:,PCNXL2:ENST00000475463:intron_variant:MODIFIER:exon5/16:c.649-1220C>T:,PCNXL2:ENST00000518351:intron_variant:MODIFIER:exon1/4:c.45-1220C>T:,PCNXL2:ENST00000324142:intron_variant:MODIFIER:exon4/7:n.711-1220C>T:,PCNXL2:ENST00000430153:intron_variant:MODIFIER:exon10/13:c.402-1220C>T:,PCNXL2:ENST00000519530:intron_variant:MODIFIER:exon1/2:n.123-1220C>T:			May play a role in tumorigenesis of colorectal carcinomas with high microsatellite instability (MSI-H)				0.0000	0.0000	0.0000														0	0					PCNX2 (inh=n/a pLI=0.00)	1	SomaticAndTreatment,			
chr1	233355151	233355151	G	A	0.4242	33	0.0000	43	fv.not_cod_spli;fv.off_target;fv.somca_depth_tum;fv.somca_depth_norm;off-target	109	PCNXL2	intron_variant	PCNXL2:ENST00000258229:intron_variant:MODIFIER:exon10/33:c.2505-1221C>T:,PCNXL2:ENST00000475463:intron_variant:MODIFIER:exon5/16:c.649-1221C>T:,PCNXL2:ENST00000518351:intron_variant:MODIFIER:exon1/4:c.45-1221C>T:,PCNXL2:ENST00000324142:intron_variant:MODIFIER:exon4/7:n.711-1221C>T:,PCNXL2:ENST00000430153:intron_variant:MODIFIER:exon10/13:c.402-1221C>T:,PCNXL2:ENST00000519530:intron_variant:MODIFIER:exon1/2:n.123-1221C>T:			May play a role in tumorigenesis of colorectal carcinomas with high microsatellite instability (MSI-H)				0.0000	0.0000	0.0000														0	0					PCNX2 (inh=n/a pLI=0.00)	2	SomaticAndTreatment,			
chr2	29432901	29432901	C	T	0.3418	79	0.0000	118	fv.not_cod_spli;fv.off_target;fv.somca_depth_tum;off-target	174	ALK	intron_variant	ALK:ENST00000389048:intron_variant:MODIFIER:exon24/28:c.3744-157G>A:,ALK:ENST00000431873:intron_variant:MODIFIER:exon2/3:c.792-1990G>A:			Neuronal orphan receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system. Transduces signals from ligands at the cell surface, through specific activation of the mitogen-activated protein kinase (MAPK) pathway. Phosphorylates almost exclusively at the first tyrosine of the Y-x-x-x-Y-Y motif. Following activation by ligand, ALK induces tyrosine phosphorylation of CBL, FRS2, IRS1 and SHC1, as well as of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Acts as a receptor for ligands pleiotrophin (PTN), a secreted growth factor, and midkine (MDK), a PTN-related factor, thus participating in PTN and MDK signal transduction. PTN-binding induces MAPK pathway activation, which is important for the anti-apoptotic signaling of PTN and regulation of cell proliferation. MDK-binding induces phosphorylation of the ALK target insulin receptor substrate (IRS1), activates mitogen-activated protein kinases (MAPKs) and PI3-kinase, resulting also in cell proliferation induction. Drives NF-kappa-B activation, probably through IRS1 and the activation of the AKT serine/threonine kinase. Recruitment of IRS1 to activated ALK and the activation of NF-kappa-B are essential for the autocrine growth and survival signaling of MDK				0.0000	0.0000	0.0000		105590 [ALK (confirmed) Neuroblastoma,susceptibility to,3,613014];												0	0					ALK (inh=n/a pLI=0.52)	1	SomaticAndTreatment,	ALK	Early trials, Pre-clinical, Case report, FDA guidelines, Clinical trial	, ENST00000389048
chr2	91635114	91635114	T	C	0.5500	20	0.0500	42	fv.not_cod_spli;fv.off_target;fv.somca_depth_tum;fv.somca_depth_norm;fv.somca_all_freq;off-target	67	RP11-685N3.1-AC018696.1	intergenic_region	RP11-685N3.1-AC018696.1:ENSG00000228325-ENSG00000226615:intergenic_region:MODIFIER::n.91635114T>C:						rs66579617	0.0000	0.0000	0.0000														0	1					RP11-685N3.1-AC018696.1 (inh=n/a pLI=n/a)	2	Mesotheliomstudie,SomaticAndTreatment,			
chr2	141625739	141625739	C	T	0.7844	334	0.0000	501	off-target	1528	LRP1B	missense_variant	LRP1B:ENST00000389484:missense_variant:MODERATE:exon26/91:c.4263G>A:p.Met1421Ile,LRP1B:ENST00000434794:missense_variant:MODERATE:exon11/14:c.1698G>A:p.Met566Ile	Six-bladed_beta-propeller__TolB-like__1_		Potential cell surface proteins that bind and internalize ligands in the process of receptor-mediated endocytosis				0.0000	0.0000	0.0000					5.982000	D	T,T,T	B,D	D,D	21.70				0	0					LRP1B (inh=n/a pLI=1.00)	1	SomaticAndTreatment,	LRP1B	Early trials	
chr3	47142993	47142993	G	A	0.8006	322	0.0000	577	off-target	1685	SETD2	missense_variant,3_prime_UTR_variant	SETD2:ENST00000409792:missense_variant:MODERATE:exon8/21:c.4970C>T:p.Pro1657Leu,SETD2:ENST00000445387:missense_variant:MODERATE:exon6/20:c.3869C>T:p.Pro1290Leu,SETD2:ENST00000431180:3_prime_UTR_variant:MODIFIER:exon5/19:c.*127C>T:,SETD2:ENST00000330022:3_prime_UTR_variant:MODIFIER:exon6/19:c.*693C>T:	SET_domain__3_	Lysine degradation	Histone methyltransferase that specifically trimethylates 'Lys-36' of histone H3 (H3K36me3) using dimethylated 'Lys-36' (H3K36me2) as substrate. Represents the main enzyme generating H3K36me3, a specific tag for epigenetic transcriptional activation. Plays a role in chromatin structure modulation during elongation by coordinating recruitment of the FACT complex and by interacting with hyperphosphorylated POLR2A. Acts as a key regulator of DNA mismatch repair in G1 and early S phase by generating H3K36me3, a mark required to recruit MSH6 subunit of the MutS alpha complex: early recruitment of the MutS alpha complex to chromatin to be replicated allows a quick identification of mismatch DNA to initiate the mismatch repair reaction. H3K36me3 also plays an essential role in the maintenance of a heterochromatic state, by recruiting DNA methyltransferase DNMT3A. H3K36me3 is also enhanced in intron-containing genes, suggesting that SETD2 recruitment is enhanced by splicing and that splicing is coupled to recruitment of elongating RNA polymerase. Required during angiogenesis. Recruited to the promoters of adenovirus 12 E1A gene in case of infection, possibly leading to regulate its expression				0.0000	0.0000	0.0000		612778 [SETD2 (provisional) Luscan-Lumish syndrome,616831];			7.778000	D	T,D,T	P,D	D	23.60				0	0					SETD2 (inh=AD pLI=1.00)	1	SomaticAndTreatment,	SETD2	Pre-clinical	
chr3	96585699	96585699	G	T	0.0275	182	0.0000	344	fv.somca_all_freq;off-target	38	EPHA6	missense_variant	EPHA6:ENST00000389672:missense_variant:MODERATE:exon2/18:c.416G>T:p.Gly139Val,EPHA6:ENST00000470610:missense_variant:MODERATE:exon2/5:c.416G>T:p.Gly139Val,EPHA6:ENST00000542517:missense_variant:MODERATE:exon2/4:c.134G>T:p.Gly45Val,EPHA6:ENST00000506569:missense_variant:MODERATE:exon2/4:c.248G>T:p.Gly83Val		Axon guidance	Receptor tyrosine kinase which binds promiscuously GPI- anchored ephrin-A family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling (By similarity)				0.0000	0.0000	0.0000					7.098000	T	D,D,D	D,D	T,T,T	27.30				0	0					EPHA6 (inh=n/a pLI=0.95)	1	SomaticAndTreatment,			
chr4	55955236	55955236	G	A	0.4732	112	0.0000	219	fv.not_cod_spli;fv.off_target;off-target	356	RP11-530I17.1,KDR	intron_variant	RP11-530I17.1:ENST00000511222:intron_variant:MODIFIER:exon3/3:n.234-3244G>A:,KDR:ENST00000263923:intron_variant:MODIFIER:exon25/29:c.3405-96C>T:		Cytokine-cytokine receptor interaction;VEGF signaling pathway;Focal adhesion	Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC	Actions of Nitric Oxide in the Heart;VEGF, Hypoxia, and Angiogenesis			0.0000	0.0000	0.0000		191306 [KDR (confirmed) Hemangioma,capillary infantile,somatic,602089|Hemangioma,capillary infantile,susceptibility to,602089];												0	0					RP11-530I17.1 (inh=n/a pLI=n/a), KDR (inh=AD pLI=0.98)	1	SomaticAndTreatment,	KDR	Pre-clinical	ENST00000263923
chr4	100239994	100239994	G	A	0.6880	250	0.0000	652	off-target	1284	ADH1B	missense_variant,5_prime_UTR_variant,3_prime_UTR_variant,non_coding_transcript_exon_variant	ADH1B:ENST00000305046:missense_variant:MODERATE:exon2/9:c.68C>T:p.Ser23Phe,ADH1B:ENST00000394887:5_prime_UTR_variant:MODIFIER:exon2/9:c.-53C>T:,ADH1B:ENST00000506651:3_prime_UTR_variant:MODIFIER:exon3/10:c.*148C>T:,ADH1B:ENST00000515694:non_coding_transcript_exon_variant:MODIFIER:exon2/9:n.2163C>T:,ADH1B:ENST00000504498:non_coding_transcript_exon_variant:MODIFIER:exon2/3:n.122C>T:	GroES-like__1_	Glycolysis / Gluconeogenesis;Fatty acid metabolism;Bile acid biosynthesis;Tyrosine metabolism;1- and 2-Methylnaphthalene degradation;3-Chloroacrylic acid degradation;Retinol metabolism;Metabolism of xenobiotics by cytochrome P450;Drug metabolism - cytochrome P450					0.0000	0.0000	0.0000		103720 [ADH1B (confirmed) Alcohol dependence,protection against,103780|Aerodigestive tract cancer,squamous cell,alcohol-related,protection against];			1.493000	T	D,D	D	T	23.20				0	0					ADH1B (inh=n/a pLI=0.19)	1	SomaticAndTreatment,			
chr5	176722306	176722306	C	A	0.0150	469	0.0000	597	fv.somca_all_freq;off-target	56	NSD1	missense_variant	NSD1:ENST00000439151:missense_variant:MODERATE:exon23/23:c.7937C>A:p.Ala2646Glu,NSD1:ENST00000354179:missense_variant:MODERATE:exon24/24:c.7130C>A:p.Ala2377Glu,NSD1:ENST00000347982:missense_variant:MODERATE:exon24/24:c.7130C>A:p.Ala2377Glu,NSD1:ENST00000361032:missense_variant:MODERATE:exon20/20:c.7628C>A:p.Ala2543Glu		Lysine degradation	Histone methyltransferase. Preferentially methylates 'Lys-36' of histone H3 and 'Lys-20' of histone H4 (in vitro). Transcriptional intermediary factor capable of both negatively or positively influencing transcription, depending on the cellular context				0.0000	0.0000	0.0000		606681 [NSD1 (confirmed) Sotos syndrome 1,117550|Leukemia,acute myeloid,601626|Beckwith-Wiedemann syndrome,130650];			1.206000	D	D,D,D,D	B,B	D,D,D,D	19.59				0	0					NSD1 (inh=AD pLI=1.00)	1	SomaticAndTreatment,			
chr7	2983827	2983827	G	A	0.3406	277	0.0000	393		459	CARD11,AC004906.3	splice_region_variant&intron_variant,non_coding_transcript_exon_variant	CARD11:ENST00000396946:splice_region_variant&intron_variant:LOW:exon5/24:c.684+19C>T:,AC004906.3:ENST00000423194:non_coding_transcript_exon_variant:MODIFIER:exon1/2:n.159G>A:		T cell receptor signaling pathway;B cell receptor signaling pathway	Involved in the costimulatory signal essential for T- cell receptor (TCR)-mediated T-cell activation. Its binding to DPP4 induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner. Activates NF-kappa-B via BCL10 and IKK. Stimulates the phosphorylation of BCL10				0.0000	0.0000	0.0000		607210 [CARD11 (provisional) B-cell expansion with NFKB and T-cell anergy,616452|Immunodeficiency 11,615206];												0	0					CARD11 (inh=AR pLI=1.00), AC004906.3 (inh=n/a pLI=n/a)	1	SomaticAndTreatment,			
chr7	6043875	6043875	A	T	0.5600	25	0.0000	34	fv.not_cod_spli;fv.off_target;fv.somca_depth_tum;fv.somca_depth_norm	85	PMS2	intron_variant	PMS2:ENST00000265849:intron_variant:MODIFIER:exon2/14:c.164-186T>A:,PMS2:ENST00000382321:intron_variant:MODIFIER:exon2/10:c.164-186T>A:,PMS2:ENST00000406569:intron_variant:MODIFIER:exon2/11:c.164-186T>A:,PMS2:ENST00000469652:intron_variant:MODIFIER:exon2/2:n.62+1749T>A:,PMS2:ENST00000380416:intron_variant:MODIFIER:exon2/4:n.243-186T>A:,PMS2:ENST00000415839:intron_variant:MODIFIER:exon1/1:n.176-186T>A:		Mismatch repair	Component of the post-replicative DNA mismatch repair system (MMR). Heterodimerizes with MLH1 to form MutL alpha. DNA repair is initiated by MutS alpha (MSH2-MSH6) or MutS beta (MSH2- MSH6) binding to a dsDNA mismatch, then MutL alpha is recruited to the heteroduplex. Assembly of the MutL-MutS-heteroduplex ternary complex in presence of RFC and PCNA is sufficient to activate endonuclease activity of PMS2. It introduces single-strand breaks near the mismatch and thus generates new entry points for the exonuclease EXO1 to degrade the strand containing the mismatch. DNA methylation would prevent cleavage and therefore assure that only the newly mutated DNA strand is going to be corrected. MulL alpha (MLH1-PMS2) interacts physically with the clamp loader subunits of DNA polymerase III, suggesting that it may play a role to recruit the DNA polymerase III to the site of the MMR. Also implicated in DNA damage signaling, a process which induces cell cycle arrest and can lead to apoptosis in case of major DNA damages				0.0000	0.0000	0.0000		600259 [PMS2 (confirmed) Mismatch repair cancer syndrome,276300|Colorectal cancer,hereditary nonpolyposis,type 4,614337];												0	0					PMS2 (inh=AR+AD pLI=0.00)	1	SomaticAndTreatment,			
chr7	56874725	56874725	C	T	0.5345	58	0.0000	65	fv.not_cod_spli;fv.off_target;fv.somca_depth_tum;fv.somca_depth_norm	174	RP11-10F11.2-RP13-580B18.1	intergenic_region	RP11-10F11.2-RP13-580B18.1:ENSG00000228303-ENSG00000233437:intergenic_region:MODIFIER::n.56874725C>T:							0.0000	0.0000	0.0000														0	0					RP11-10F11.2-RP13-580B18.1 (inh=n/a pLI=n/a)	1	SomaticAndTreatment,			
chr7	128767246	128767246	C	T	0.5628	694	0.0000	594	fv.not_cod_spli;fv.off_target	1414	RP11-286H14.4	non_coding_transcript_exon_variant	RP11-286H14.4:ENST00000467614:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.675C>T:							0.0000	0.0000	0.0000														0	0					RP11-286H14.4 (inh=n/a pLI=n/a)	1	SomaticAndTreatment,			
chr7	140434597	140434597	G	T	0.1386	116	0.0154	76	fv.not_cod_spli;fv.off_target;fv.somca_depth_norm;fv.somca_all_freq	81	BRAF	intron_variant	BRAF:ENST00000288602:intron_variant:MODIFIER:exon17/17:c.2128-27C>A:,BRAF:ENST00000496384:intron_variant:MODIFIER:exon8/9:c.949-27C>A:,BRAF:ENST00000479537:intron_variant:MODIFIER:exon5/5:c.*185-27C>A:,BRAF:ENST00000497784:intron_variant:MODIFIER:exon18/18:c.*1578-27C>A:		MAPK signaling pathway;ErbB signaling pathway;mTOR signaling pathway;Focal adhesion;Natural killer cell mediated cytotoxicity;Long-term potentiation;Long-term depression;Regulation of actin cytoskeleton;Insulin signaling pathway;Colorectal cancer;Renal cell carcinoma;Pancreatic cancer;Endometrial cancer;Glioma;Prostate cancer;Thyroid cancer;Melanoma;Bladder cancer;Chronic myeloid leukemia;Acute myeloid leukemia;Non-small cell lung cancer	Involved in the transduction of mitogenic signals from the cell membrane to the nucleus. May play a role in the postsynaptic responses of hippocampal neuron	MAPKinase Signaling Pathway			0.0000	0.0000	0.0000		164757 [BRAF (confirmed) Melanoma,malignant,somatic|Colorectal cancer,somatic|Adenocarcinoma of lung,somatic,211980|Nonsmall cell lung cancer,somatic|Cardiofaciocutaneous syndrome,115150|Noonan syndrome 7,613706|LEOPARD syndrome 3,613707];												0	0					BRAF (inh=AR+AD pLI=1.00)	2	SomaticAndTreatment,TEST_SomaticAndTreatment,	BRAF	NCCN guidelines, Early trials, Pre-clinical, Case report, FDA guidelines, Late trials	ENST00000288602, 
chr7	140453135	140453135	C	T	0.5168	568	0.0000	656		1230	BRAF	synonymous_variant,3_prime_UTR_variant	BRAF:ENST00000288602:synonymous_variant:LOW:exon15/18:c.1800G>A:p.Val600Val,BRAF:ENST00000496384:synonymous_variant:LOW:exon6/10:c.621G>A:p.Val207Val,BRAF:ENST00000479537:synonymous_variant:LOW:exon2/6:c.84G>A:p.Val28Val,BRAF:ENST00000497784:3_prime_UTR_variant:MODIFIER:exon16/19:c.*1250G>A:		MAPK signaling pathway;ErbB signaling pathway;mTOR signaling pathway;Focal adhesion;Natural killer cell mediated cytotoxicity;Long-term potentiation;Long-term depression;Regulation of actin cytoskeleton;Insulin signaling pathway;Colorectal cancer;Renal cell carcinoma;Pancreatic cancer;Endometrial cancer;Glioma;Prostate cancer;Thyroid cancer;Melanoma;Bladder cancer;Chronic myeloid leukemia;Acute myeloid leukemia;Non-small cell lung cancer	Involved in the transduction of mitogenic signals from the cell membrane to the nucleus. May play a role in the postsynaptic responses of hippocampal neuron	MAPKinase Signaling Pathway			0.0000	0.0000	0.0000	COSM249890	164757 [BRAF (confirmed) Melanoma,malignant,somatic|Colorectal cancer,somatic|Adenocarcinoma of lung,somatic,211980|Nonsmall cell lung cancer,somatic|Cardiofaciocutaneous syndrome,115150|Noonan syndrome 7,613706|LEOPARD syndrome 3,613707];												0	0					BRAF (inh=AR+AD pLI=1.00)	1	SomaticAndTreatment,	BRAF	NCCN guidelines, Early trials, Pre-clinical, Case report, FDA guidelines, Late trials	ENST00000288602, 
chr7	140453136	140453136	A	T	0.5185	568	0.0000	661		1272	BRAF	missense_variant,3_prime_UTR_variant	BRAF:ENST00000288602:missense_variant:MODERATE:exon15/18:c.1799T>A:p.Val600Glu,BRAF:ENST00000496384:missense_variant:MODERATE:exon6/10:c.620T>A:p.Val207Glu,BRAF:ENST00000479537:missense_variant:MODERATE:exon2/6:c.83T>A:p.Val28Glu,BRAF:ENST00000497784:3_prime_UTR_variant:MODIFIER:exon16/19:c.*1249T>A:	Serine-threonine/tyrosine-protein_kinase__1_,Protein_kinase-like_domain__1_,Protein_kinase__catalytic_domain__1_,	MAPK signaling pathway;ErbB signaling pathway;mTOR signaling pathway;Focal adhesion;Natural killer cell mediated cytotoxicity;Long-term potentiation;Long-term depression;Regulation of actin cytoskeleton;Insulin signaling pathway;Colorectal cancer;Renal cell carcinoma;Pancreatic cancer;Endometrial cancer;Glioma;Prostate cancer;Thyroid cancer;Melanoma;Bladder cancer;Chronic myeloid leukemia;Acute myeloid leukemia;Non-small cell lung cancer	Involved in the transduction of mitogenic signals from the cell membrane to the nucleus. May play a role in the postsynaptic responses of hippocampal neuron	MAPKinase Signaling Pathway		rs113488022	0.0000	0.00002	0.00000	COSM476	164757 [BRAF (confirmed) Melanoma,malignant,somatic|Colorectal cancer,somatic|Adenocarcinoma of lung,somatic,211980|Nonsmall cell lung cancer,somatic|Cardiofaciocutaneous syndrome,115150|Noonan syndrome 7,613706|LEOPARD syndrome 3,613707];	RCV000014992.14 [pathogenic]; RCV000014993.14 [pathogenic]; RCV000014994.14 [pathogenic]; RCV000022677.14 [pathogenic]; RCV000037936.2 [pathogenic]; RCV000067669.13 [pathogenic]; RCV000080903.4 [pathogenic]; RCV000208763.1 [pathogenic]; 		9.197000,9.197000	T,	D,	D,	D,	32.00				3	2		[import GPD] Christopher Schroeder 2013-05-07 09:14:08 -type: lit / general -link: http://www.ncbi.nlm.nih.gov/pubmed/21663470?dopt=Abstract&holding=npg -doi: 10.1056/NEJMoa1014209 BRAF mutations in hairy-cell leukemia.  [import GPD] Christopher Schroeder 2013-05-07 09:14:45 -type: lit / general -link: http://www.ncbi.nlm.nih.gov/pubmed/22210875?dopt=Abstract&holding=npg -doi: 10.1182/blood-2011-09-379339 Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation.  [import GPD] Christopher Schroeder 2013-05-02 17:26:11 -type: lit / druggable -link: http://www.nejm.org/doi/full/10.1056/NEJMc1215697?query=TOC -drugs: vemurafenib BRAF V600E Inhibition in Anaplastic Thyroid Cancer  [import GPD] Christopher Schroeder 2013-05-07 18:21:28 -type: lit / general -link: http://www.ncbi.nlm.nih.gov/pubmed/22395615?dopt=Abstract&holding=npg -doi: 10.1038/ncomms1727 Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance.  [import GPD] Christopher Schroeder 2013-05-15 11:43:10 -type: lit / preclinical study -link: http://www.nature.com/nature/journal/v483/n7387/full/nature10868.html -doi: 10.1038/nature10868 -drugs: vemurafenib, cetuximab, gefitinib, panitumumab Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.  => Our data suggest that BRAF(V600E) mutant colon cancers (approximately 8–10% of all colon cancers2, 3, 5), for which there are currently no targeted treatment options available, might benefit from combination therapy consisting of BRAF and EGFR inhibitors.  [import GPD] Christopher Schroeder 2013-05-03 17:12:18 -type: lit / druggable -link: http://www.nejm.org/doi/full/10.1056/NEJMoa1103782 -drugs: vemurafenib Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation  [import GPD] Christopher Schroeder 2013-05-28 15:50:19 -type: lit / general -link: http://www.ncbi.nlm.nih.gov/pubmed/20818844 -doi: 10.1056/NEJMoa1002011 -drugs: vemurafenib Inhibition of mutated, activated BRAF in metastatic melanoma. => Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients.  [import GPD] Christopher Schroeder 2013-06-05 15:32:18 -type: lit / druggable -link: http://jco.ascopubs.org/content/early/2013/06/03/JCO.2012.45.7739?papetoc -doi: 10.1200/JCO.2012.45.7739 -drugs: vemurafenib Rapid Response to Vemurafenib in a Heavily Pretreated Patient With Hairy Cell Leukemia and a BRAF Mutation  [import GPD] Christopher Schroeder 2013-09-04 10:29:28 -type: lit / preclinical study -link: http://www.ncbi.nlm.nih.gov/pubmed/18676837 -doi: 10.1158/0008-5472.CAN-08-1430 -drugs: selumetinib, Trametinib Tumors harboring BRAF V600E mutations lack this negative feedback loop and are sensitive to MEK inhibitors.  [import GPD] Christopher Schroeder 2013-12-22 15:16:45 -type: lit / clinical trial -link: http://jco.ascopubs.org/content/31/35/e448?cmpid=jco_etoc_10December2013 -doi: 10.1200/JCO.2013.50.4118 -drugs: dabrafenib, Trametinib BRAF Inhibitor–Driven Tumor Proliferation in a KRAS-Mutated Colon Carcinoma Is Not Overcome by MEK1/2 Inhibition => First, caution must be exercised when using BRAFis in patients or populations that might harbor RAS-mutated cells, be they in skin, bowel, or other sites.  [import GPD] Christopher Schroeder 2013-06-05 15:27:37 -type: case report -link: http://jco.ascopubs.org/content/early/2013/06/03/JCO.2012.47.6143?papetoc -doi: 10.1200/JCO.2012.47.6143 -drugs: vemurafenib, radiation Dramatic Response Induced by Vemurafenib in a BRAF V600E-Mutated Lung Adenocarcinoma. Radiosensitizing effect of vemurafenib ("should probably not be combined with radiation").			BRAF (inh=AR+AD pLI=1.00)	9	SomaticAndTreatment,TEST_cfDNA_ThruPLEX_Tag-seq,	BRAF	NCCN guidelines, Early trials, Pre-clinical, Case report, FDA guidelines, Late trials	ENST00000288602, 
chr8	48815129	48815129	C	T	0.2171	258	0.0000	404	off-target	302	PRKDC	missense_variant&splice_region_variant,splice_region_variant&non_coding_transcript_exon_variant	PRKDC:ENST00000314191:missense_variant&splice_region_variant:MODERATE:exon27/87:c.3269G>A:p.Arg1090Lys,PRKDC:ENST00000338368:missense_variant&splice_region_variant:MODERATE:exon27/86:c.3269G>A:p.Arg1090Lys,PRKDC:ENST00000523565:splice_region_variant&non_coding_transcript_exon_variant:LOW:exon27/86:n.3326G>A:,PRKDC:ENST00000518216:splice_region_variant&non_coding_transcript_exon_variant:LOW:exon27/85:n.3321G>A:	Armadillo-like_helical__1_,Armadillo-type_fold__1_	Non-homologous end-joining;Cell cycle	Serine/threonine-protein kinase that acts as a molecular sensor for DNA damage. Involved in DNA nonhomologous end joining (NHEJ) required for double-strand break (DSB) repair and V(D)J recombination. Must be bound to DNA to express its catalytic properties. Promotes processing of hairpin DNA structures in V(D)J recombination by activation of the hairpin endonuclease artemis (DCLRE1C). The assembly of the DNA-PK complex at DNA ends is also required for the NHEJ ligation step. Required to protect and align broken ends of DNA. May also act as a scaffold protein to aid the localization of DNA repair proteins to the site of damage. Found at the ends of chromosomes, suggesting a further role in the maintenance of telomeric stability and the prevention of chromosomal end fusion. Also involved in modulation of transcription. Recognizes the substrate consensus sequence [ST]-Q. Phosphorylates 'Ser-139' of histone variant H2AX/H2AFX, thereby regulating DNA damage response mechanism. Phosphorylates DCLRE1C, c-Abl/ABL1, histone H1, HSPCA, c-jun/JUN, p53/TP53, PARP1, POU2F1, DHX9, SRF, XRCC1, XRCC1, XRCC4, XRCC5, XRCC6, WRN, MYC and RFA2. Can phosphorylate C1D not only in the presence of linear DNA but also in the presence of supercoiled DNA. Ability to phosphorylate p53/TP53 in the presence of supercoiled DNA is dependent on C1D	Cell Cycle: G2/M Checkpoint;FAS signaling pathway ( CD95 );HIV-I Nef: negative effector of Fas and TNF;TNFR1 Signaling Pathway			0.0000	0.0000	0.0000		600899 [PRKDC (confirmed) Immunodeficiency 26,with or without neurologic abnormalities,615966];			7.442000	T	D,D	D,D,D	T,T	26.30				0	0					PRKDC (inh=AR pLI=1.00)	1	SomaticAndTreatment,			
chr8	59338957	59338957	C	T	0.0667	76	0.0000	110	fv.not_cod_spli;fv.off_target;fv.somca_depth_tum;off-target	67	UBXN2B,RP11-114M5.1	intron_variant	UBXN2B:ENST00000399598:intron_variant:MODIFIER:exon2/7:c.189-4121C>T:,RP11-114M5.1:ENST00000510501:intron_variant:MODIFIER:exon1/1:n.177+111G>A:,UBXN2B:ENST00000522978:intron_variant:MODIFIER:exon3/6:n.289-4121C>T:,UBXN2B:ENST00000520732:intron_variant:MODIFIER:exon2/5:c.189-6762C>T:,UBXN2B:ENST00000523409:intron_variant:MODIFIER:exon2/8:c.189-4121C>T:,UBXN2B:ENST00000521796:intron_variant:MODIFIER:exon1/4:c.24-4121C>T:			Adapter protein required for Golgi and endoplasmic reticulum biogenesis. Involved in Golgi and endoplasmic reticulum maintenance during interphase and in their reassembly at the end of mitosis. The complex formed with VCP has membrane fusion activity; membrane fusion activity requires USO1-GOLGA2 tethering and BET1L. VCPIP1 is also required, but not its deubiquitinating activity			rs557805702	0.000199681	0.0000	0.0000														0	0					UBXN2B (inh=n/a pLI=0.49), RP11-114M5.1 (inh=n/a pLI=n/a)	1	SomaticAndTreatment,			
chr8	125313615	125313615	G	A	0.2752	109	0.0037	268	fv.not_cod_spli;fv.off_target;off-target	201	RP11-383J24.2	non_coding_transcript_exon_variant	RP11-383J24.2:ENST00000517740:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.60G>A:							0.0000	0.0000	0.0000														0	0					RP11-383J24.2 (inh=n/a pLI=n/a)	1	SomaticAndTreatment,			
chr9	133710321	133710321	C	T	0.1541	318	0.0000	395	fv.not_cod_spli;fv.off_target;off-target	239	ABL1	intron_variant	ABL1:ENST00000372348:intron_variant:MODIFIER:exon1/10:c.137-19130C>T:,ABL1:ENST00000393293:intron_variant:MODIFIER:exon1/1:c.137-19133C>T:		ErbB signaling pathway;Cell cycle;Axon guidance;Pathogenic Escherichia coli infection;EPEC;Chronic myeloid leukemia	Non-receptor tyrosine-protein kinase that plays a role in many key processes linked to cell growth and survival such as cytoskeleton remodeling in response to extracellular stimuli, cell motility and adhesion, receptor endocytosis, autophagy, DNA damage response and apoptosis. Coordinates actin remodeling through tyrosine phosphorylation of proteins controlling cytoskeleton dynamics like WASF3 (involved in branch formation); ANXA1 (involved in membrane anchoring); DBN1, DBNL, CTTN, RAPH1 and ENAH (involved in signaling); or MAPT and PXN (microtubule-binding proteins). Phosphorylation of WASF3 is critical for the stimulation of lamellipodia formation and cell migration. Involved in the regulation of cell adhesion and motility through phosphorylation of key regulators of these processes such as BCAR1, CRK, CRKL, DOK1, EFS or NEDD9. Phosphorylates multiple receptor tyrosine kinases and more particularly promotes endocytosis of EGFR, facilitates the formation of neuromuscular synapses through MUSK, inhibits PDGFRB-mediated chemotaxis and modulates the endocytosis of activated B-cell receptor complexes. Other substrates which are involved in endocytosis regulation are the caveolin (CAV1) and RIN1. Moreover, ABL1 regulates the CBL family of ubiquitin ligases that drive receptor down-regulation and actin remodeling. Phosphorylation of CBL leads to increased EGFR stability. Involved in late-stage autophagy by regulating positively the trafficking and function of lysosomal components. ABL1 targets to mitochondria in response to oxidative stress and thereby mediates mitochondrial dysfunction and cell death. ABL1 is also translocated in the nucleus where it has DNA-binding activity and is involved in DNA-damage response and apoptosis. Many substrates are known mediators of DNA repair: DDB1, DDB2, ERCC3, ERCC6, RAD9A, RAD51, RAD52 or WRN. Activates the proapoptotic pathway when the DNA damage is too severe to be repaired. Phosphorylates TP73, a primary regulator for this type of damage- induced apoptosis. Phosphorylates the caspase CASP9 on 'Tyr-153' and regulates its processing in the apoptotic response to DNA damage. Phosphorylates PSMA7 that leads to an inhibition of proteasomal activity and cell cycle transition blocks. ABL1 acts also as a regulator of multiple pathological signaling cascades during infection. Several known tyrosine-phosphorylated microbial proteins have been identified as ABL1 substrates. This is the case of A36R of Vaccinia virus, Tir (translocated intimin receptor) of pathogenic E.coli and possibly Citrobacter, CagA (cytotoxin- associated gene A) of H.pylori, or AnkA (ankyrin repeat-containing protein A) of A.phagocytophilum. Pathogens can highjack ABL1 kinase signaling to reorganize the host actin cytoskeleton for multiple purposes, like facilitating intracellular movement and host cell exit. Finally, functions as its own regulator through autocatalytic activity as well as through phosphorylation of its inhibitor, ABI1	ATM Signaling Pathway;Cell Cycle: G1/S Check Point ;Lissencephaly gene (LIS1) in neuronal migration and development;Tumor Suppressor Arf Inhibits Ribosomal Biogenesis			0.0000	0.0000	0.0000		189980 [ABL1 (confirmed) Leukemia,Philadelphia chromosome-positive,resistant to imatinib];												0	0					ABL1 (inh=AD pLI=1.00)	1	SomaticAndTreatment,	ABL1	Pre-clinical, European LeukemiaNet guidelines, FDA guidelines, NCCN guidelines	ENST00000318560, 
chr11	27911345	27911345	C	T	0.6568	169	0.0018	550	fv.not_cod_spli;fv.off_target;off-target	890	RP11-1033A18.1	non_coding_transcript_exon_variant	RP11-1033A18.1:ENST00000530115:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.1236G>A:							0.0000	0.0000	0.0000														0	0					RP11-1033A18.1 (inh=n/a pLI=n/a)	2	SomaticAndTreatment,			
chr11	75479127	75479127	A	C	0.5833	14	0.0476	21	fv.not_cod_spli;fv.off_target;fv.somca_depth_tum;fv.somca_depth_norm;fv.somca_all_freq;off-target	31	CTD-2530H12.1,DGAT2	intron_variant	CTD-2530H12.1:ENST00000499390:intron_variant:MODIFIER:exon1/3:n.154+412T>G:,DGAT2:ENST00000603276:intron_variant:MODIFIER:exon1/5:c.-153+8456A>C:		Glycerolipid metabolism;Retinol metabolism	Essential acyltransferase that catalyzes the terminal and only committed step in triacylglycerol synthesis by using diacylglycerol and fatty acyl CoA as substrates. Required for synthesis and storage of intracellular triglycerides. Probably plays a central role in cytosolic lipid accumulation. In liver, is primarily responsible for incorporating endogenously synthesized fatty acids into triglycerides (By similarity). Functions also as an acyl-CoA retinol acyltransferase (ARAT)				0.0000	0.0000	0.0000														0	0					CTD-2530H12.1 (inh=n/a pLI=n/a), DGAT2 (inh=n/a pLI=0.00)	1	SomaticAndTreatment,			
chr12	46285797	46285797	A	T	0.7136	213	0.0000	541	off-target	1141	ARID2	stop_gained,non_coding_transcript_exon_variant	ARID2:ENST00000334344:stop_gained:HIGH:exon18/21:c.5065A>T:p.Lys1689*,ARID2:ENST00000422737:stop_gained:HIGH:exon18/20:c.4618A>T:p.Lys1540*,ARID2:ENST00000444670:stop_gained:HIGH:exon10/13:c.3895A>T:p.Lys1299*,ARID2:ENST00000457135:stop_gained:HIGH:exon4/8:c.889A>T:p.Lys297*,ARID2:ENST00000479608:non_coding_transcript_exon_variant:MODIFIER:exon12/15:n.4356A>T:			Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Required for the stability of the SWI/SNF chromatin remodeling complex SWI/SNF-B (PBAF). May be involved in targeting the complex to different genes. May be involved in regulating transcriptional activation of cardiac genes				0.0000	0.0000	0.0000					8.581000					50.00				0	0					ARID2 (inh=n/a pLI=1.00)	1	SomaticAndTreatment,			
chr12	49434964	49434964	G	A	0.6047	133	0.0000	414	off-target	632	KMT2D	missense_variant	KMT2D:ENST00000301067:missense_variant:MODERATE:exon31/54:c.6589C>T:p.Pro2197Ser			Histone methyltransferase. Methylates 'Lys-4' of histone H3 (H3K4me). H3K4me represents a specific tag for epigenetic transcriptional activation. Acts as a coactivator for estrogen receptor by being recruited by ESR1, thereby activating transcription				0.0000	0.0000	0.0000		602113 [KMT2D (provisional) Kabuki syndrome 1,147920];			0.813000	T	D	B	T	0.00				0	0					KMT2D (inh=AD pLI=1.00)	1	SomaticAndTreatment,	KMT2D	Pre-clinical	
chr12	133257641	133257641	C	A	0.2857	91	0.0000	176	fv.not_cod_spli;fv.off_target;fv.somca_depth_tum;off-target	185	POLE	intron_variant,non_coding_transcript_exon_variant	POLE:ENST00000320574:intron_variant:MODIFIER:exon2/48:c.204+83G>T:,POLE:ENST00000537064:intron_variant:MODIFIER:exon2/48:c.204+83G>T:,POLE:ENST00000535270:intron_variant:MODIFIER:exon2/47:c.204+83G>T:,POLE:ENST00000539618:intron_variant:MODIFIER:exon1/1:n.142+83G>T:,POLE:ENST00000539357:non_coding_transcript_exon_variant:MODIFIER:exon2/2:n.337G>T:		Purine metabolism;Pyrimidine metabolism;DNA replication;Base excision repair;Nucleotide excision repair	Participates in DNA repair and in chromosomal DNA replication				0.0000	0.0000	0.0000		174762 [POLE (provisional) Colorectal cancer,susceptibility to,12,615083|FILS syndrome,615139];												0	0					POLE (inh=AR pLI=0.00)	1	SomaticAndTreatment,			
chr13	28631326	28631326	G	A	0.7083	24	0.0000	82	fv.not_cod_spli;fv.off_target;fv.somca_depth_tum;fv.somca_depth_norm;off-target	194	FLT3	intron_variant	FLT3:ENST00000380982:intron_variant:MODIFIER:exon4/23:c.484+158C>T:,FLT3:ENST00000241453:intron_variant:MODIFIER:exon4/23:c.484+158C>T:,FLT3:ENST00000380987:intron_variant:MODIFIER:exon4/24:c.484+158C>T:,FLT3:ENST00000537084:intron_variant:MODIFIER:exon4/22:c.484+158C>T:		Cytokine-cytokine receptor interaction;Hematopoietic cell lineage;Acute myeloid leukemia	Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B. Activation of wild-type FLT3 causes only marginal activation of STAT5A or STAT5B. Mutations that cause constitutive kinase activity promote cell proliferation and resistance to apoptosis via the activation of multiple signaling pathways	Erythrocyte Differentiation Pathway			0.0000	0.0000	0.0000		136351 [FLT3 (confirmed) Leukemia,acute myeloid,reduced survival in,somatic,601626|Leukemia,acute myeloid,somatic,601626|Leukemia,acute lymphoblastic,somatic,613065];												0	0					FLT3 (inh=n/a pLI=0.61)	1	SomaticAndTreatment,	FLT3	Pre-clinical, Case report	
chr15	21137012	21137012	C	T	0.4110	73	0.0000	180	fv.not_cod_spli;fv.off_target;fv.somca_depth_tum;off-target	239	NF1P1	intron_variant	NF1P1:ENST00000604105:intron_variant:MODIFIER:exon6/16:n.1084+95G>A:							0.0000	0.0000	0.0000														0	0					NF1P1 (inh=n/a pLI=n/a)	1	SomaticAndTreatment,			
chr15	88669219	88669219	C	T	0.8333	6	0.0000	15	fv.not_cod_spli;fv.off_target;fv.somca_depth_tum;fv.somca_depth_norm;off-target	36	NTRK3	intron_variant	NTRK3:ENST00000360948:intron_variant:MODIFIER:exon12/18:c.1396+283G>A:,NTRK3:ENST00000394480:intron_variant:MODIFIER:exon13/18:c.1396+283G>A:,NTRK3:ENST00000557856:intron_variant:MODIFIER:exon10/15:c.1372+283G>A:,NTRK3:ENST00000355254:intron_variant:MODIFIER:exon12/17:c.1396+283G>A:,NTRK3:ENST00000357724:intron_variant:MODIFIER:exon11/17:c.1372+283G>A:,NTRK3:ENST00000542733:intron_variant:MODIFIER:exon11/15:c.1102+283G>A:,NTRK3:ENST00000558676:intron_variant:MODIFIER:exon10/13:c.1372+283G>A:,NTRK3:ENST00000317501:intron_variant:MODIFIER:exon12/14:c.1396+283G>A:,NTRK3:ENST00000558306:intron_variant:MODIFIER:exon1/2:n.30+1174G>A:,NTRK3:ENST00000540489:intron_variant:MODIFIER:exon11/13:c.1396+283G>A:,NTRK3:ENST00000560017:intron_variant:MODIFIER:exon3/3:c.208+283G>A:,NTRK3:ENST00000557897:intron_variant:MODIFIER:exon1/1:n.91+283G>A:			Receptor for neurotrophin-3 (NT-3). This is a tyrosine- protein kinase receptor. Known substrates for the trk receptors are SHC1, PI-3 kinase, and PLCG1. The different isoforms do not have identical signaling properties				0.0000	0.0000	0.0000														0	0					NTRK3 (inh=n/a pLI=0.98)	1	SomaticAndTreatment,	NTRK3	Pre-clinical	
chr15	90633941	90633941	G	A	0.8462	52	0.0000	145	fv.not_cod_spli;fv.off_target;fv.somca_depth_tum;off-target	409	IDH2	intron_variant	IDH2:ENST00000330062:intron_variant:MODIFIER:exon2/10:c.208-65C>T:,IDH2:ENST00000539790:intron_variant:MODIFIER:exon1/8:c.-17-1962C>T:,IDH2:ENST00000560061:intron_variant:MODIFIER:exon1/8:c.116-1962C>T:,IDH2:ENST00000559482:intron_variant:MODIFIER:exon2/7:c.207+844C>T:,IDH2:ENST00000540499:intron_variant:MODIFIER:exon2/10:c.52-65C>T:		Citrate cycle (TCA cycle);Glutathione metabolism;Reductive carboxylate cycle (CO2 fixation)	Plays a role in intermediary metabolism and energy production. It may tightly associate or interact with the pyruvate dehydrogenase complex				0.0000	0.0000	0.0000		147650 [IDH2 (confirmed) D-2-hydroxyglutaric aciduria 2,613657];												0	0					IDH2 (inh=AD pLI=0.38)	1	SomaticAndTreatment,	IDH2	Pre-clinical, Early trials	, ENST00000330062
chr16	50827612	50827612	G	T	0.4620	184	0.0000	405	fv.not_cod_spli;fv.off_target;off-target	552	CYLD,RP11-327F22.4	intron_variant	CYLD:ENST00000311559:intron_variant:MODIFIER:exon18/19:c.2469+37G>T:,RP11-327F22.4:ENST00000564510:intron_variant:MODIFIER:exon2/2:n.456+8422C>A:,CYLD:ENST00000569418:intron_variant:MODIFIER:exon16/17:c.2460+37G>T:,CYLD:ENST00000540145:intron_variant:MODIFIER:exon17/18:c.2469+37G>T:,CYLD:ENST00000564326:intron_variant:MODIFIER:exon15/16:c.2460+37G>T:,CYLD:ENST00000566206:intron_variant:MODIFIER:exon16/17:c.2460+37G>T:,CYLD:ENST00000398568:intron_variant:MODIFIER:exon16/17:c.2460+37G>T:,CYLD:ENST00000427738:intron_variant:MODIFIER:exon16/17:c.2469+37G>T:,CYLD:ENST00000568704:intron_variant:MODIFIER:exon12/13:c.1914+37G>T:,RP11-327F22.4:ENST00000575917:intron_variant:MODIFIER:exon1/1:n.27+4515C>A:,CYLD:ENST00000562884:intron_variant:MODIFIER:exon1/1:c.48+37G>T:			Protease that specifically cleaves 'Lys-63'-linked polyubiquitin chains. Has endodeubiquitinase activity. Plays an important role in the regulation of pathways leading to NF-kappa-B activation. Contributes to the regulation of cell survival, proliferation and differentiation via its effects on NF-kappa-B activation. Negative regulator of Wnt signaling. Inhibits HDAC6 and thereby promotes acetylation of alpha-tubulin and stabilization of microtubules. Plays a role in the regulation of microtubule dynamics, and thereby contributes to the regulation of cell proliferation, cell polarization, cell migration, and angiogenesis. Required for normal cell cycle progress and normal cytokinesis. Inhibits nuclear translocation of NF-kappa-B. Plays a role in the regulation of inflammation and the innate immune response, via its effects on NF-kappa-B activation. Dispensable for the maturation of intrathymic natural killer cells, but required for the continued survival of immature natural killer cells. Negatively regulates TNFRSF11A signaling and osteoclastogenesis (By similarity)			rs200543731	0.0000	0.00056	0.00061		605018 [CYLD (provisional) Cylindromatosis,familial,132700|Brooke-Spiegler syndrome,605041|Trichoepithelioma,multiple familial,1,601606];												0	1					CYLD (inh=AD pLI=0.99), RP11-327F22.4 (inh=n/a pLI=n/a)	1	SomaticAndTreatment,			
chr17	8108512	8108512	G	A	0.5203	127	0.0000	267	fv.not_cod_spli;off-target	414	AURKB	intron_variant	AURKB:ENST00000316199:intron_variant:MODIFIER:exon8/8:c.864+22C>T:,AURKB:ENST00000534871:intron_variant:MODIFIER:exon7/7:c.738+22C>T:,AURKB:ENST00000585124:intron_variant:MODIFIER:exon8/8:c.861+22C>T:,AURKB:ENST00000584972:intron_variant:MODIFIER:exon4/4:c.552+124C>T:,AURKB:ENST00000535053:intron_variant:MODIFIER:exon6/6:c.*296+22C>T:,AURKB:ENST00000578549:intron_variant:MODIFIER:exon7/7:c.765+22C>T:,AURKB:ENST00000580998:intron_variant:MODIFIER:exon6/6:c.*208+22C>T:,AURKB:ENST00000578753:intron_variant:MODIFIER:exon2/2:n.383+22C>T:			Serine/threonine-protein kinase component of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis. The CPC complex has essential functions at the centromere in ensuring correct chromosome alignment and segregation and is required for chromatin-induced microtubule stabilization and spindle assembly. Involved in the bipolar attachment of spindle microtubules to kinetochores and is a key regulator for the onset of cytokinesis during mitosis. Required for central/midzone spindle assembly and cleavage furrow formation. AURKB phosphorylates the CPC complex subunits BIRC5/survivin, CDCA8/borealin and INCENP. Phosphorylation of INCENP leads to increased AURKB activity. Other known AURKB substrates involved in centromeric functions and mitosis are CENPA, DES/desmin, GPAF, KIF2C, NSUN2, RACGAP1, SEPT1, VIM/vimentin, GSG2/Haspin, and histone H3. A positive feedback loop involving GSG2 and AURKB contributes to localization of CPC to centromeres. Phosphorylation of VIM controls vimentin filament segregation in cytokinetic process, whereas histone H3 is phosphorylated at 'Ser-10' and 'Ser-28' during mitosis. A positive feedback between GSG2 and AURKB contributes to CPC localization. AURKB is also required for kinetochore localization of BUB1 and SGOL1. Phosphorylation of p53/TP53 negatively regulates its transcriptional activity			rs767347858	0.0000	0.00001	0.00001														0	0					AURKB (inh=n/a pLI=0.01)	1	SomaticAndTreatment,			
chr17	59886139	59886139	G	A	0.4870	155	0.0000	242	fv.not_cod_spli;off-target	423	BRIP1	intron_variant	BRIP1:ENST00000259008:intron_variant:MODIFIER:exon6/19:c.628-21C>T:,BRIP1:ENST00000577598:intron_variant:MODIFIER:exon5/17:c.628-21C>T:			DNA-dependent ATPase and 5' to 3' DNA helicase required for the maintenance of chromosomal stability. Acts late in the Fanconi anemia pathway, after FANCD2 ubiquitination. Involved in the repair of DNA double-strand breaks by homologous recombination in a manner that depends on its association with BRCA1			rs759424776	0.0000	0.00003	0.00001		605882 [BRIP1 (confirmed) Breast cancer,early-onset,114480|Fanconi anemia,complementation group J,609054];												0	0					BRIP1 (inh=AR+AD pLI=0.00)	1	SomaticAndTreatment,			
chr18	25585776	25585776	C	T	0.5093	162	0.0000	326	fv.not_cod_spli;fv.off_target;off-target	516	CDH2	intron_variant	CDH2:ENST00000269141:intron_variant:MODIFIER:exon6/15:c.847+37G>A:,CDH2:ENST00000399380:intron_variant:MODIFIER:exon5/14:c.754+37G>A:		Cell adhesion molecules (CAMs)	Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. CDH2 may be involved in neuronal recognition mechanism. In hippocampal neurons, may regulate dendritic spine density (By similarity)				0.0000	0.0000	0.0000														0	0					CDH2 (inh=n/a pLI=0.90)	1	SomaticAndTreatment,			
chr18	45396615	45396615	G	A	0.3889	18	0.0000	34	fv.not_cod_spli;fv.off_target;fv.somca_depth_tum;fv.somca_depth_norm;off-target	85	SMAD2	intron_variant	SMAD2:ENST00000262160:intron_variant:MODIFIER:exon3/10:c.326+231C>T:,SMAD2:ENST00000402690:intron_variant:MODIFIER:exon3/10:c.326+231C>T:,SMAD2:ENST00000356825:intron_variant:MODIFIER:exon2/9:c.237-808C>T:,SMAD2:ENST00000586040:intron_variant:MODIFIER:exon1/8:c.237-808C>T:,SMAD2:ENST00000591214:intron_variant:MODIFIER:exon2/8:c.237-808C>T:,SMAD2:ENST00000587353:intron_variant:MODIFIER:exon2/3:n.195+231C>T:,SMAD2:ENST00000587269:intron_variant:MODIFIER:exon4/5:c.326+231C>T:,SMAD2:ENST00000586514:intron_variant:MODIFIER:exon4/5:c.326+231C>T:,SMAD2:ENST00000587421:intron_variant:MODIFIER:exon3/3:c.326+231C>T:		Cell cycle;Wnt signaling pathway;TGF-beta signaling pathway;Adherens junction;Colorectal cancer;Pancreatic cancer	Receptor-regulated SMAD (R-SMAD) that is an intracellular signal transducer and transcriptional modulator activated by TGF-beta (transforming growth factor) and activin type 1 receptor kinases. Binds the TRE element in the promoter region of many genes that are regulated by TGF-beta and, on formation of the SMAD2/SMAD4 complex, activates transcription. May act as a tumor suppressor in colorectal carcinoma. Positively regulates PDPK1 kinase activity by stimulating its dissociation from the 14-3-3 protein YWHAQ which acts as a negative regulator	TGF beta signaling pathway			0.0000	0.0000	0.0000														0	0					SMAD2 (inh=n/a pLI=0.99)	1	SomaticAndTreatment,			
chr19	1220504	1220504	G	A	0.4648	214	0.0000	376	off-target	572	STK11	splice_region_variant&synonymous_variant,splice_region_variant,splice_region_variant&non_coding_transcript_exon_variant,3_prime_UTR_variant,non_coding_transcript_exon_variant	STK11:ENST00000326873:splice_region_variant&synonymous_variant:LOW:exon4/10:c.597G>A:p.Glu199Glu,STK11:ENST00000593219:splice_region_variant:LOW:exon5/9:c.*422G>A:,STK11:ENST00000589152:splice_region_variant&non_coding_transcript_exon_variant:LOW:exon4/8:n.687G>A:,STK11:ENST00000585851:splice_region_variant&synonymous_variant:LOW:exon2/3:c.423G>A:p.Glu141Glu,STK11:ENST00000593219:3_prime_UTR_variant:MODIFIER:exon5/9:c.*422G>A:,STK11:ENST00000586358:non_coding_transcript_exon_variant:MODIFIER:exon4/5:n.420G>A:,STK11:ENST00000591133:non_coding_transcript_exon_variant:MODIFIER:exon1/3:n.493G>A:		mTOR signaling pathway;Adipocytokine signaling pathway	Tumor suppressor serine/threonine-protein kinase that controls the activity of AMP-activated protein kinase (AMPK) family members, thereby playing a role in various processes such as cell metabolism, cell polarity, apoptosis and DNA damage response. Acts by phosphorylating the T-loop of AMPK family proteins, leading to promote their activity: phosphorylates PRKAA1, PRKAA2, BRSK1, BRSK2, MARK1, MARK2, MARK3, MARK4, NUAK1, NUAK2, SIK1, SIK2, SIK3 and SNRK but not MELK. Also phosphorylates non-AMPK family proteins such as STRADA and possibly p53/TP53. Acts as a key upstream regulator of AMPK by mediating phosphorylation and activation of AMPK catalytic subunits PRKAA1 and PRKAA2: it thereby regulates inhibition of signaling pathways that promote cell growth and proliferation when energy levels are low, glucose homeostasis in liver, activation of autophagy when cells undergo nutrient deprivation, B-cell differentiation in the germinal center in response to DNA damage. Also acts as a regulator of cellular polarity by remodeling the actin cytoskeleton. Required for cortical neurons polarization by mediating phosphorylation and activation of BRSK1 and BRSK2, leading to axon initiation and specification. Involved in DNA damage response: interacts with p53/TP53 and recruited to the CDKN1A/WAF1 promoter to participate in transcription activation. Able to phosphorylate p53/TP53; the relevance of such result in vivo is however unclear and phosphorylation may be indirect and mediated by downstream STK11/LKB1 kinase NUAK1 Also acts as a mediator p53/TP53-dependent apoptosis via interaction with p53/TP53: translocates to mitochondrion during apoptosis and regulates p53/TP53-dependent apoptosis pathways				0.0000	0.0000	0.0000		602216 [STK11 (confirmed) Peutz-Jeghers syndrome,175200|Melanoma,malignant,somatic|Pancreatic cancer,260350|Testicular tumor,somatic,273300];												0	0					STK11 (inh=AD pLI=0.98)	1	SomaticAndTreatment,	STK11	Pre-clinical, Case report	, ENST00000326873
chr19	45856646	45856646	T	G	0.1987	151	0.0000	376	fv.not_cod_spli;fv.off_target;off-target	219	ERCC2	intron_variant	ERCC2:ENST00000391945:intron_variant:MODIFIER:exon17/22:c.1666-54A>C:,ERCC2:ENST00000588652:intron_variant:MODIFIER:exon4/9:n.1754-54A>C:,ERCC2:ENST00000391942:intron_variant:MODIFIER:exon6/11:n.837-54A>C:,ERCC2:ENST00000391944:intron_variant:MODIFIER:exon15/20:c.1432-54A>C:,ERCC2:ENST00000391941:intron_variant:MODIFIER:exon16/20:c.1594-54A>C:,ERCC2:ENST00000587376:intron_variant:MODIFIER:exon7/7:c.*117-54A>C:		Nucleotide excision repair	ATP-dependent 5'-3' DNA helicase, component of the core- TFIIH basal transcription factor. Involved in nucleotide excision repair (NER) of DNA by opening DNA around the damage, and in RNA transcription by RNA polymerase II by anchoring the CDK-activating kinase (CAK) complex, composed of CDK7, cyclin H and MAT1, to the core-TFIIH complex. Involved in the regulation of vitamin-D receptor activity. As part of the mitotic spindle-associated MMXD complex it plays a role in chromosome segregation. Might have a role in aging process and could play a causative role in the generation of skin cancers				0.0000	0.0000	0.0000		126340 [ERCC2 (confirmed) Xeroderma pigmentosum,group D,278730|Trichothiodystrophy 1,photosensitive,601675|Cerebrooculofacioskeletal syndrome 2,610756];												0	0					ERCC2 (inh=AR pLI=0.00)	1	SomaticAndTreatment,	ERCC2	Early trials	
chr19	52693105	52693105	A	G	0.4500	20	0.0000	21	fv.not_cod_spli;fv.off_target;fv.somca_depth_tum;fv.somca_depth_norm;off-target	46	CTD-2525I3.2-PPP2R1A	intergenic_region	CTD-2525I3.2-PPP2R1A:ENSG00000267927-ENSG00000105568:intergenic_region:MODIFIER::n.52693105A>G:							0.0000	0.0000	0.0000		605983 [PPP2R1A (provisional) Mental retardation,autosomal dominant 36,616362];												0	0					CTD-2525I3.2-PPP2R1A (inh=n/a pLI=n/a)	1	SomaticAndTreatment,			
chrY	13574306	13574306	C	T	0.8235	85	0.0000	163	fv.not_cod_spli;fv.off_target;fv.somca_depth_tum;off-target	519	RP11-295P22.1-RP11-295P22.2	intergenic_region	RP11-295P22.1-RP11-295P22.2:ENSG00000270242-ENSG00000271375:intergenic_region:MODIFIER::n.13574306C>T:							0.0000	0.0000	0.0000														0	0					RP11-295P22.1-RP11-295P22.2 (inh=n/a pLI=n/a)	1	SomaticAndTreatment,			
chrMT	5979	5979	G	C	0.9694	359	0.0000	15	fv.off_target;fv.somca_depth_norm;off-target	244	MT-CO1	missense_variant	MT-CO1:ENST00000361624:missense_variant:MODERATE:exon1/1:c.76G>C:p.Ala26Pro		Oxidative phosphorylation	Cytochrome c oxidase is the component of the respiratory chain that catalyzes the reduction of oxygen to water. Subunits 1- 3 form the functional core of the enzyme complex. CO I is the catalytic subunit of the enzyme. Electrons originating in cytochrome c are transferred via the copper A center of subunit 2 and heme A of subunit 1 to the bimetallic center formed by heme A3 and copper B	Electron Transport Reaction in Mitochondria			0.0000	0.0000	0.0000														0	0					MT-CO1 (inh=n/a pLI=n/a)	1	SomaticAndTreatment,			
